The effect of Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist,after cardiac surgery

The effect of Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist,after cardiac surgery - The effect of Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist,after cardiac surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011039

Enrollment

100

Registered

2013-07-01

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients who receive off-pump coronary artery bypass surgery

Interventions

Tolvapta is administrated in &quot

Tolvaptan&quot

group, instead of regular diuretic medication regular diuretic treatment will be administrated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who received elective OPCAB surgery

Exclusion criteria

Exclusion criteria: history of dialysis severe renal failure (eGFR<15mL/min/1.73m2) emergent surgery maximum blood pressure is less than 100mmHg any other patient who are in contraindicated of Torvaptan

Design outcomes

Primary

Measure	Time frame
Change of Body Weight	—

Secondary

Measure	Time frame
arrhythmia, pleural effusion, fluid volume from drainage tube, postoperative hospital stay, volume of urine, proportion of electrolyte in blood and urine, BUN, creatinine, eGFP, blood pressure, heart rate, adverse event related to cardiac or vascular system	—

Countries

Japan

Contacts

Public ContactSatoshi Matsushita

Juntendo University Faculty of Medicine Department of Cardiovascular Surgery

saty-m@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026